Duloxetine for treating painful neuropathy or chronic pain (Q24240634)

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine vs. placebo in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

EFNS guidelines on pharmacological treatment of neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Therapy Insight: fibromyalgia--a different type of pain needing a different type of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

A retrospective pooled analysis of duloxetine safety in 23,983 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Epidemiology and treatment of neuropathic pain: the UK primary care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

A cost-utility comparison of four first-line medications in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

What do we know about duloxetine's mode of action? Evidence from animals to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Neuropathic pain: redefinition and a grading system for clinical and research purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Is there a place for duloxetine?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007115.PUB2